Hepatitis of unknown aetiology in children - epidemiological overview of cases reported in Europe, 1 January to 16 June 2022.

Autor: Romaní Vidal A; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Vaughan A; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Innocenti F; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.; Epidemiology Unit, Regional Health Agency of Tuscany, Florence, Italy., Colombe S; World Health Organization Regional Office for Europe, Copenhagen, Denmark., Nerlander L; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Rachwal N; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Ciancio BC; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Mougkou A; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Carvalho C; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Delgado E; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Mook P; World Health Organization Regional Office for Europe, Copenhagen, Denmark., de Muylder G; Sciensano, Epidemiology of Infectious Diseases, Brussels, Belgium., Peeters M; Sciensano, Infectious Diseases in Humans, Viral Diseases, National Reference Centre for Hepatitis Viruses, Brussels, Belgium., Tenev T; National Reference Laboratory Hepatitis viruses, NCIPD-Virology, Sofia, Bulgaria., Golkocheva-Markova E; National Reference Laboratory Hepatitis viruses, NCIPD-Virology, Sofia, Bulgaria., Vorobieva Solholm Jensen V; Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark., Koch A; Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Figoni J; Santé Publique France, the National Public Health Agency, Saint-Maurice, France., Brouard C; Santé Publique France, the National Public Health Agency, Saint-Maurice, France., Nikolopoulou G; Greek National Public Health Organization (EODY), Athens, Greece., Zisouli A; Greek National Public Health Organization (EODY), Athens, Greece., Murphy N; Health Service Executive HPSC surveillance scientist on the National IMT for hepatitis, Dublin, Ireland., Broderick A; Children's Health Ireland (CHI), Crumlin, Ireland., Goldberg L; Israel Ministry of Health, Jerusalem, Israel., Rich R; Israel Ministry of Health, Jerusalem, Israel., Hecht Sagie L; Israel Ministry of Health, Jerusalem, Israel., Tosti ME; National Centre for Global Health - Istituto Superiore di Sanità, Rome, Italy., Suligoi B; Infectious Disease Department - Istituto Superiore di Sanità, Rome, Italy., Joosten R; National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Bilthoven, the Netherlands., Pijnacker R; National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Bilthoven, the Netherlands., Fjeldheim I; Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway., Heen E; Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway., Stępień M; Department of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland., Polański P; Department of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland., Tato Marinho R; Gastroenterology and Hepatology Department, Hospital S. Maria; Medical School of Lisbon; National Programme for Viral Hepatitis, Portugal Ministry of Health, Lisbon, Portugal., Vieira Martins J; Directorate of Information and Analysis, Directorate-General of Health, Lisbon, Portugal., Varela C; National Centre of Epidemiology, Carlos III Institute of Health, CIBERESP, Madrid, Spain., Avellón A; National Centre of Microbiology, Carlos III Institute of Health, CIBERESP, Madrid, Spain., Andersson E; Public Health Agency of Sweden, Solna, Sweden., Jansson Mörk M; Public Health Agency of Sweden, Solna, Sweden., Mandal S; United Kingdom Health Security Agency Epidemiology Cell, London, United Kingdom., Watson C; United Kingdom Health Security Agency Epidemiology Cell, London, United Kingdom., Coughlan L; United Kingdom Health Security Agency Epidemiology Cell, London, United Kingdom., Chand M; United Kingdom Health Security Agency Incident Director, London, United Kingdom., Neill C; Public Health Agency Northern Ireland, Belfast, United Kingdom., Bradley DT; Public Health Agency Northern Ireland, Belfast, United Kingdom., Li K; Regional Virology Laboratory Belfast Health and Social Care Trust, Northern Ireland, Belfast, United Kingdom., O'Leary M; Clinical and Protecting Health Directorate, Public Health Scotland, Glasgow, United Kingdom., McInnes N; West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom., Williams CJ; Public Health Wales, Cardiff, United Kingdom., Moore C; Public Health Wales, Cardiff, United Kingdom., Gjini A; Public Health Wales, Cardiff, United Kingdom., Duffell E; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Pebody R; World Health Organization Regional Office for Europe, Copenhagen, Denmark.
Jazyk: angličtina
Zdroj: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2022 Aug; Vol. 27 (31).
DOI: 10.2807/1560-7917.ES.2022.27.31.2200483
Abstrakt: Following the report of an excess in paediatric cases of severe acute hepatitis of unknown aetiology by the United Kingdom (UK) on 5 April 2022, 427 cases were reported from 20 countries in the World Health Organization European Region to the European Surveillance System TESSy from 1 January 2022 to 16 June 2022. Here, we analysed demographic, epidemiological, clinical and microbiological data available in TESSy. Of the reported cases, 77.3% were 5 years or younger and 53.5% had a positive test for adenovirus, 10.4% had a positive RT-PCR for SARS-CoV-2 and 10.3% were coinfected with both pathogens. Cases with adenovirus infections were significantly more likely to be admitted to intensive care or high-dependency units (OR = 2.11; 95% CI: 1.18-3.74) and transplanted (OR = 3.36; 95% CI: 1.19-9.55) than cases with a negative test result for adenovirus, but this was no longer observed when looking at this association separately between the UK and other countries. Aetiological studies are needed to ascertain if adenovirus plays a role in this possible emergence of hepatitis cases in children and, if confirmed, the mechanisms that could be involved.
Databáze: MEDLINE